Not only adults, nasal polyps can also occur in children. Polyps are an inflammation of the nasal membranes and sinuses that ...

The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...

The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030, registering a CAGR of 5.6% from 2021 to 2030. WILMINGTON, DE, UNITED STATES, March 13, 2025 ...

A new CT-scan-based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Recent studies examine the burden of CRSwNP, looking at quality of life in patients and caregivers and assessing how CRSwNP ...

is approved as an add-on maintenance treatment for severe asthma. To examine the efficacy and safety of the medication in severe, uncontrolled chronic rhinosinusitis with nasal polyps, researchers ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent of these cases. Even after surgical treatment, the recurrence rate of CRSwNP remains high, ranging from 20 to 60 percent ...

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...